Showing posts with label cilia. Show all posts
Showing posts with label cilia. Show all posts

Monday, 17 November 2008

How Cilia Make Us Asymmetric

FoxJ1 helps cilia beat a path to asymmetry Monday, 17 November 2008 New work at the Salk Institute for Biological Studies reveals how a genetic switch, known as FoxJ1, helps developing embryos tell their left from their right. While at first glance the right and left sides of our bodies are identical to each other, this symmetry is only skin-deep. Below the surface, some of our internal organs are shifted sideways — heart and stomach to the left, liver and appendix to the right. Creating this left-right asymmetry is a key step in early embryonic development, and requires hundreds of tiny hair-like structures called nodal cilia to beat in unison. Like microscopic conductors, cilia orchestrate a flow of embryonic fluid from right to left that allows the growing tissues to orient themselves. The current study provides new insight into the crucial role FoxJ1 plays in directing the development of these cilia. "This one transcription factor regulates a whole suite of genes needed to coordinate the formation of nodal cilia," says Christopher R. Kintner, Ph.D., a professor in the Molecular Neurobiology Laboratory, who led the study. Strikingly, FoxJ1 can induce cilia to form on the surface of cells that do not usually have them, the Salk researchers report in this week's early online edition of Nature Genetics. Their findings may one day lead to a cure for ciliopathies, diseases that result from malfunctioning or damaged cilia. Cilia — tiny hair-like protrusions found on certain cell types — come in three flavours. Motile cilia crowd the surface of specialized cells and move in harmony to generate liquid flow. They are used to sweep mucus and dirt out of our lungs and in females to propel the egg from the ovary through the Fallopian tube into the uterus. Unlike motile cilia, sensory cilia usually number just one per cell and are used to relay information back to the cell about its surroundings. A third and less characterized subtype are nodal cilia. Nodal cilia share certain features with both their sensory and motile counterparts; they exist one per cell yet function to generate the fluid movement during embryo development that is crucial to forming the left-right asymmetry.


In the developing embryo, nodal cilia (shown in green) orchestrate a flow of embryonic fluid from right to left that allows the growing tissues to orientate themselves. Credit: Courtesy of Jennifer Stubbs, Salk Institute for Biological Studies.
"We were interested in the developmental cues that drive the formation of these different cilia subtypes," says Kintner. Clues from previous work in mice persuaded Kintner and his team to take a closer look at cilia in the South African clawed frog Xenopus, a model popular with developmental biologists, and zebrafish. In mice, FoxJ1 is needed to drive the formation of motile but not sensory cilia. The Salk researchers depleted FoxJ1 in both Xenopus and zebrafish by injecting embryos with morpholinos, synthetic DNA-like structures that bind to nucleic acids and work like dimmer switches to turn down gene expression. When FoxJ1 was turned down, nodal cilia development was disrupted, causing organ displacement and defects in the left-right asymmetry. The real surprise came when the scientists increased the levels of FoxJ1. "We started seeing cilia popping up all over the place," says Kintner, "and they were not random subtypes; they looked just like the nodal cilia that form on the cells to generate the embryonic left-right flow." "These ectopic cilia were really interesting," adds Jennifer Stubbs, first author of the study and a graduate student in the Kintner lab, "and no one had been able to show them in any other system." These findings call into question current theories as to how FoxJ1 regulates motile cilia. Motile cilia are anchored to the cell surface at sites called basal bodies, and FoxJ1's role in their development was thought to act primarily by regulating this docking process. Since activating FoxJ1 was sufficient to drive the formation of cilia in usually cilia-less cells, however, Kintner and colleagues reasoned that FoxJ1 must play a broader role in promoting cilia development. They tested this hypothesis using microarray analysis to determine what genes FoxJ1 activated. Indeed, FoxJ1 increased the levels of a host of genes involved in motile cilia development rather than just a small set relating to the basal body. "This really suggests that at least in Xenopus, FoxJ1 is a master-regulator of ciliogenesis and doesn't just play a role in basal body docking," says Stubbs. Kintner and colleagues are currently investigating in closer detail the suite of genes activated by FoxJ1 to further understand its mode of action. “Doing so might help develop novel therapies to treat ciliopathies, whose symptoms range from respiratory defects to infertility. In many diseases such as chronic asthmas and cystic fibrosis, trouble clearing mucus causes defects where the ciliated cells begin to die," says Kintner, "and knowing about the dominant pathways that drive differentiation of ciliated cells types might allow us to do something prevent that situation." "It may provide a way of repairing ciliated cells that are already there, enabling them to regrow their cilia," says Jennifer Stubbs. ......... ZenMaster
For more on stem cells and cloning, go to CellNEWS at http://cellnews-blog.blogspot.com/ and http://www.geocities.com/giantfideli/index.html

Tuesday, 22 July 2008

Spinal Cord Stem Cells May Act as Nerve Repair System

Cells for spinal-cord repair identified, could lead to nonsurgical treatment for injuries Tuesday, 22 July 2008 Researcher at the Karolinska Institute in Sweden and MIT's Picower Institute for Learning and Memory has pinpointed stem cells within the spinal cord that, if persuaded to differentiate into more healing cells and fewer scarring cells following an injury, may lead to a new, non-surgical treatment for debilitating spinal-cord injuries. The work, reported in the July issue of the journal PLoS (Public Library of Science) Biology, was done by Jonas Frisén’s group at the Department of Cell and Molecular Biology, Karolinska Institute, Stockholm, Sweden. Their results could lead to drugs that might restore some degree of mobility to the 30,000 people worldwide afflicted each year with spinal-cord injuries. In a developing embryo, stem cells differentiate into all the specialized tissues of the body. In adults, stem cells act as a repair system, replenishing specialized cells, but also maintaining the normal turnover of regenerative organs such as blood, skin or intestinal tissues. The tiny number of stem cells in the adult spinal cord proliferates slowly or rarely, and fails to promote regeneration on their own. But recent experiments show that these same cells, grown in the lab and returned to the injury site, can restore some function in paralyzed rodents and primates. The researchers at the Karolinska Institute and MIT found that neural stem cells in the adult spinal cord are limited to a layer of cube- or column-shaped, cilia-covered cells called ependymal cells. These cells make up the thin membrane lining the inner-brain ventricles and the connecting central column of the spinal cord. "We have been able to genetically mark this neural stem cell population and then follow their behavior," Konstantinos Meletis said, the first author of the study and presently a postdoctoral fellow at the Picower Institute at MIT in Cambridge, Massachusetts, USA. "We find that these cells proliferate upon spinal cord injury, migrate toward the injury site and differentiate over several months."


Ependymal cells in the adult spinal cord self-renew in vivo. Stack of 14 images depicting vimentin expressing ependymal cells (purple) of the central canal that have incorporated BrdU (have divided, orange). Spinal cord neurons are labelled with NeuN (white). Credit: Image/Design by Marie Carlén; confocal image by Fanie Barnabé-Heider.
The study uncovers the molecular mechanism underlying the tantalizing results of the rodent and primate and goes one step further: By identifying for the first time where this subpopulation of cells is found, they pave a path toward manipulating them with drugs to boost their inborn ability to repair damaged nerve cells. "The ependymal cells' ability to turn into several different cell types upon injury makes them very interesting from an intervention aspect: Imagine if we could regulate the behaviour of this stem cell population to repair damaged nerve cells," Meletis said. Upon injury, ependymal cells proliferate and migrate to the injured area, producing a mass of scar-forming cells, plus fewer cells called oligodendrocytes. The oligodendrocytes restore the myelin, or coating, on nerve cells' long, slender, electrical impulse-carrying projections called axons. Myelin is like the layer of plastic insulation on an electrical wire; without it, nerve cells don't function properly. "The limited functional recovery typically associated with central nervous system injuries is in part due to the failure of severed axons to regrow and reconnect with their target cells in the peripheral nervous system that extends to our arms, hands, legs and feet," Meletis said. "The function of axons that remain intact after injury in humans is often compromised without insulating sheaths of myelin." If scientists could genetically manipulate ependymal cells to produce more myelin and less scar tissue after a spinal cord injury, they could potentially avoid or reverse many of the debilitating effects of this type of injury, the researchers said. This study was supported by grants from the Swedish Research Council, the Swedish Cancer Society, the Foundation for Strategic Research, the Karolinska Institute, EuroStemCell and the Christopher and Dana Reeve Foundation. Reference: Spinal Cord Injury Reveals Multilineage Differentiation of Ependymal Cells Konstantinos Meletis, Fanie Barnabé-Heider, Marie Carlén, Emma Evergren, Nikolay Tomilin, Oleg Shupliakov, Jonas Frisén PLoS Biol 6(7): e182 doi:10.1371/journal.pbio.0060182 ......... ZenMaster
For more on stem cells and cloning, go to CellNEWS at http://cellnews-blog.blogspot.com/ and http://www.geocities.com/giantfideli/index.html

Monday, 10 March 2008

Genetic Research Unveils Common Origins for Distinct Clinical Diagnoses

Genetic Research Unveils Common Origins for Distinct Clinical Diagnoses Monday, 10 March 2008 Researchers at Johns Hopkins have discovered that two clinically different inherited syndromes are in fact variations of the same disorder. Reporting in the April issue of Nature Genetics, the team suggests that at least for this class of disorders, the total number and “strength” of genetic alterations an individual carries throughout the genome can generate a range of symptoms wide enough to appear like different conditions. “We’re finally beginning to blur the boundaries encompassing some of these diseases by showing that they share the same molecular underpinnings,” says Nicholas Katsanis, Ph.D., an associate professor of ophthalmology at the McKusick-Nathans Institute of Genetic Medicine at Hopkins. “This is important progress for several reasons. First, knowing what’s going on molecularly and being able to integrate rarer conditions under common mechanisms allows us to potentially help more people at once. Second, clinicians can finally begin to offer more accurate diagnoses based on what really matters: the state of affairs at the cellular/biochemical level. In time, this will empower genetic counselling and much improved patient management.” Katsanis’s team studies Bardet-Biedl syndrome (BBS), a rare so-called ciliopathy that is characterized by a combination of vision loss, obesity, diabetes, extra digits and mental defects and caused by faulty cilia, tiny hair-like projections found on almost every cell of the body. Recently they started looking at another disease, Meckel-Gruber syndrome (MKS), which also shows cilia dysfunction but is clinically distinct from BBS and generally associated with prenatal or newborn death. “While these two groups of patients exhibit such different clinical outcomes, the genes associated with both syndromes all seemed to be pointing at the same culprit: cilia,” says Katsanis. “So we wondered if BBS and MKS might actually represent different flavours of the same disease.” The researchers sequenced the MKS genes from 200 BBS patients and found six families that, in addition to carrying BBS genetic mutations, also carried mutations in MKS genes. To figure out what, if any, effect these MKS mutations have on BBS, the team used a system they previously developed in zebrafish. Knocking out BBS genes in zebrafish generates short fish with even shorter tails, among other malformations. Injecting normal BBS genes into these fish rescues them, resulting in normal looking fish. The researchers reasoned that if MKS and BBS are indeed the same condition, then fish with the MKS genes knocked out should mimic the BBS knockout fish. They did. The team then went on to test mutant versions of MKS genes in BBS fish and found that three genes originally attributed to MKS do indeed cause BBS or render the BBS defects more pronounced, increasing the number of BBS genes to 14 in total. “From a clinical perspective, these two syndromes look nothing alike, but molecularly, the genes involved clearly participate in the same fundamental processes,” says Katsanis. “This means that Meckel-Gruber and Bardet-Biedel actually represent a continuum of one disease. This never would have been discovered in the clinic-only molecular analysis can reveal these things.” But what does this mean for clinicians and the diagnosis and treatment of these syndromes? Katsanis hopes that the growing body of molecular data will help move medicine away from symptom-defined syndromes, which can leave clinicians struggling with ambiguous diagnoses, to approaching disorders from a molecular standpoint. “We now have the possibility of merging several rare disorders,” he says. “And their gross sum now turns out to be fairly common; hopefully this will now put them on the radar for drug development and other therapies.” Authors on the paper are Carmen Leitch, Norann Zaghloul, Erica Davis and Katsanis, all of Hopkins; Corrine Stoetzel and Helene Dollfus of Université Louis Pasteur, Strasbourg, France; Anna Diaz-Font, Suzanne Rix and Philip Beales of University College London, UK; Majid Al-Fadhel and Wafaa Eyaid of King Fahad Hospital, Riyadh, Saudi Arabia; Richard Alan Lewis of Baylor College of Medicine, Houston, Texas.; Eyal Banin of Hadassah-Hebrew University Hospital, Jerusalem, Israel; and Jose Badano, previously of Hopkins and now at the Institut Pasteur de Montevideo, Uruguay. ......... ZenMaster


For more on stem cells and cloning, go to CellNEWS at http://www.geocities.com/giantfideli/index.html